Andreas Emmenegger has served as our CFO since February 2007. Prior to joining Molecular Partners, he was the CFO of Glycart Biotechnology AG where he had a leading role in the CHF 235 million trade sale to F. Hoffmann-La Roche AG in 2005. Mr. Emmenegger was Head of Strategic Alliance Finance (Genentech) for Roche Headquarters, Basel, Switzerland. He has 25 years of experience as CFO of several public and private multinational companies, over 15 years of which have been in the biotechnology industry. He led our SIX Swiss Exchange IPO in 2014 (SIX: MOLN) and the Nasdaq IPO in 2021 (NASDAQ: MOLN). In addition, Mr. Emmenegger has more than 10 years of international industry experience in banking, capital markets, mergers and acquisitions and human resources. Since 2016, he has been a member of the board of directors of the Luzerner Kantonalbank, Switzerland, a publicly listed bank. Mr. Emmenegger holds a degree in finance, economics and business administration as well as an Executive MBA degree from IESE Business School, Barcelona.